TABLE 23Probability of first stroke among patients with SCD by age group and health state per 3-month cycle

Age (years)Health state
Transfusion > 200 cm/secondNo transfusion > 200 cm/secondNo transfusion < 200 cm/second
Probability (%)SourceProbability (%)SourceProbability (%)Source
2–70.20Adams (2005)352.5Adams 2005350.01Assumption
8–180.10Ohene-Frempong (1998)271.25Data from Ohene-Frempong (1998),27 adjusted based on effect size from the STOP trial350.01Assumption
19–300.13Ohene-Frempong (1998)270.13Ohene-Frempong (1998)270.13Ohene-Frempong (1998)27
31+0.22Data from Ohene-Frempong (1998),27 averaged for ages0.22Data from Ohene-Frempong (1998),27 averaged for ages0.22Data from Ohene-Frempong (1998),27 averaged for ages

From: 5, Assessment of cost-effectiveness

Cover of The Clinical Effectiveness and Cost-Effectiveness of Primary Stroke Prevention in Children with Sickle Cell Disease: A Systematic Review and Economic Evaluation
The Clinical Effectiveness and Cost-Effectiveness of Primary Stroke Prevention in Children with Sickle Cell Disease: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 16.43.
Cherry MG, Greenhalgh J, Osipenko L, et al.
Southampton (UK): NIHR Journals Library; 2012 Nov.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.